http://verygoodnewsisrael.blogspot.com/
ISRAEL’S MEDICAL ACHIEVEMENTS
Gaucher’s treatment also works for Covid-19. In animal tests, Israel’s Institute for Biological Research has found two treatments for the genetic disorder Gaucher’s disease are also effective against Covid-19 and other viruses (e.g. West Nile). Cerdelga is already approved for Gaucher’s and Venglustat may be fast-tracked.
https://www.timesofisrael.com/gauchers-disease-drugs-also-fight-covid-19-israeli-defense-lab-finds/
Testing Nitric Oxide treatment on Covid-19 patients. (TY Atid-EDI) Israel’s Beyond Air develops LungFit – a revolutionary Nitric Oxide (NO) generator and delivery system. The US FDA and Health Canada have approved the use of LungFit in COVID-19 treatment trials in both countries.
https://www.beyondair.net/news-media/press-releases/detail/101/beyond-air-to-initiate-clinical-study-evaluating-high https://www.beyondair.net/news-media/press-releases/detail/105/beyond-air-receives-approval-from-health-canada-to-study
Israeli-Italian partners for Covid-19 treatment. Israeli biotech Kamada (see here) has partnered Italy’s Kedrion to develop a human plasma-derived Anti-SARs-COV-2 product. Kamada will use its proprietary IgG platform technology and Kedrion will provide plasma from donors who have recovered from the virus.
https://www.kedrion.com/kedrion-and-kamada-announce-collaboration-anti-covid-19-igg-0
Patch for monitoring Covid-19 patients. (TY Atid-EDI) Israel’s G Medical has received Emergency Use Authorization from the US FDA for its Vital Signs Monitoring System (VSMS) ECG Patch. It can be used to monitor Covid-19 patients whose treatment includes medication that may cause life-threatening arrhythmias.
https://gmedinnovations.com/products/#prod https://www.youtube.com/watch?v=XRaL2OzzGoY
Treating diabetic children in Texas. (TY Atid-EDI) Israel’s DreaMed Diabetes (reported here previously) is integrating its Advisor Pro software at Texas Children’s Hospital. It allows diabetic children to be monitored remotely and avoids the risk of them (and their parents / guardians) being infected in hospital with Covid-19.
https://finder.startupnationcentral.org/company_page/dreamed-diabetes
https://dreamed-diabetes.com/advisor/
The ICU of the (near) future. HealthSpace 2030, Israel’s high-tech Intensive Care Unit of the future was unveiled in the ARC center of Sheba hospital. 11 technologies integrate augmented reality, communication, monitoring, AI, sensing, and robotic technologies to maximize care and comfort while minimizing risk to staff.
https://www.israel21c.org/hospital-icu-of-the-future-prepares-israel-for-second-corona-wave/
Cancer treatment gets $0.9 million boost. (TY Atid-EDI) Israel’s VBL Therapeutics (reported here previously) has been awarded a grant of up to $0.9 million by the Israel Innovation Authority. It will support the Phase 3 study of VBL’s lead candidate VB-111 for the treatment of platinum-resistant ovarian cancer.
http://ir.vblrx.com/news-releases/news-release-details/vbl-therapeutics-awarded-32-million-nis-non-dilutive-grant https://www.youtube.com/watch?v=SnNsZYrpT_w
Funding for 16 research projects on personalized medicine. The Israel Precision Medicine Partnership (IPMP – reported here previously), has granted another NIS 60 million to 16 projects researching into specific targeted personalized medicine that can treat ailments such as autism, cancers and trauma.
https://www.timesofisrael.com/16-israeli-research-projects-on-personalized-medicine-get-millions-in-funding/
Personalized pregnancy care. Israel’s NUVO has partnered with Jerusalem’s Hadassah hospital to develop an AI platform for accurate decision-making about pregnancy complications. NUVO has also just received US FDA approval for its INVU device (reported here previously) to be used in monitoring maternal fetal heart rate.
https://www.prnewswire.com/news-releases/nuvo-group-announces-partnership-with-hadassah-hebrew-university-medical-center-to-develop-innovative-pregnancy-population-management-platform-301058487.html
A better medical trial experience. Israel’s Habitu (see here) develops a platform specifically targeting clinical trials and patient support programs in community-based healthcare. It provides flexible, continuous, emotional, professional and procedural support to patients, leading to more efficient trials and lower drop-out rates.
https://www.habitu.health/
Heart stent gets Breakthrough status. (TY Atid-EDI) Israel’s Endospan (reported here previously) has been granted Breakthrough Device Designation from the U.S. FDA for its NEXUS Aortic Arch Stent Graft System. It already has the CE Mark of European approval.
https://www.businesswire.com/news/home/20200419005001/en/FDA-Grants-NEXUS%E2%84%A2-Aortic-Arch-Stent-Graft
Decoding the immune system. Israel’s Immunai is developing a technological platform that aims to map the entire immune system for better detection, diagnosis, and treatment of disease. It uses single cell genomics that could in the future unlock the secrets of infections, cancer and autoimmune diseases.
https://www.calcalistech.com/ctech/articles/0,7340,L-3822891,00.html https://www.immunai.com/